UPDATED: Novartis partners with Bristol-Myers Squibb as immuno-oncology deal frenzy heats up

John Carroll Novartis is prepping new studies that will test how well three of its oncology drugs–the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia–do ...

Novartis’ LCZ696 kindles megablockbuster projections with impressive PhIII heart data

John Carroll Novartis told the world back in March that its experimental heart drug LCZ696 had delivered the goods early in a pivotal study, allowing for a quick wrap of the Phase III ...

Novartis sales flag on Diovan generics, but CEO promises cost cuts will fuel profits

Tracy Staton Take a look at Novartis' second-quarter results for reasons why it engineered that big asset swap-and-sale with GlaxoSmithKline and Eli Lilly. The two units Novartis ...

Novartis accused again of kickback tactics in new whistleblower suit

Eric Palmer Kickback accusations have yet again been raised against Novartis, a company that four years ago promised to live by a new integrity code. A former exec now suggests she ...

Novartis’ Enbrel beater nears a soon-to-crowd psoriasis market

Damian Garde Novartis' in-development drug secukinumab beat out the blockbuster Enbrel in improving symptoms of psoriasis in Phase III, improving the company's odds of success ...

UPDATE: Ranbaxy’s generic of Novartis blockbuster Diovan approved for launch

Eric Palmer The long-delayed and highly anticipated launch of generic Diovan is on the way, which is a bummer for Novartis and a huge boost for Indian drugmaker Ranbaxy Laboratories. ...

Novartis nabs Merck exec Bruno Strigini to head up oncology business

Tracy Staton Novartis wooed one of Merck & Co.'s top executives to take the helm at its oncology unit. FiercePharma News

Transgene takes a hit as Novartis shreds $800M option deal

John Carroll France's Transgene took a hit this morning after the biotech announced that Novartis had decided to pass on its option for the therapeutic cancer vaccine TG4010. But ...

Novartis grabs early FDA approval of lung cancer drug Zykadia

John Carroll After a quick march through the clinic, Novartis has won early FDA approval for the new "breakthrough" lung cancer drug ceritinib (or LDK378), which will now ...

Pfizer, Novartis and 3 others put an extra $1M each into Q1 lobbying

Eric Palmer Big Pharma companies, like other corporate beings, spend millions on lobbying in Washington, DC. In fact, a handful of companies spent $ 1 million more each in the first ...

Novartis hopes new COPD study data will draw patients from Glaxo’s Advair

Carly Helfand Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of ...

GSK and Novartis reshape EU biotech, Celgene and Hyperion in Euro deals, U.K. cell therapy grows

Nick Paul Taylor In the latest edition of our weekly EuroBiotech Report, the card shuffling at GlaxoSmithKline and Novartis is raising questions about the future of several companies. ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS